FIELD study

High Density Lipoprotein Microchapters
Home
Patient information
Overview
Historical Perspective
Classification
Physiology
Pathophysiology
Causes Low HDL High HDL
Epidemiology and Demographics
Screening
Natural History, Complications and Prognosis
Diagnosis
HDL Laboratory Test
Treatment
Medical Therapy
Prevention
Future or Investigational Therapies
Clinical Trials
Landmark Trials
List of All Trials
Case Studies
Case #1
FIELD study On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of FIELD study All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on FIELD study
CDC on FIELD study
FIELD study in the news
Blogs on FIELD study
Directions to Hospitals Treating High density lipoprotein
Risk calculators and risk factors for FIELD study

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Official Title

Fenofibrate Intervention and Event Lowering in Diabetes

Objective

The objective of this study is to determine the risk of fatal coronary heart disease among subjects with type 2 diabetes who are administered fenofibrate.

Timeline

Timeline
Start Date	01/01/1998
End Date	31/12/2005
Status	Completed

Study Description

Study Description
Study Type	Randomized
Study Details
Primary Purpose
Condition	Diabetes Mellitus type 2
Intervention	Fenofibrate Placebo
Population Size	9,795